The European Medicine Agency is updating its PRIME scheme, a programme of regulatory support for developers of novel medicines meeting a major public health need, in order to tighten reviews. The programme was introduced in 2016 to give special assistance to developers of advanced therapy medicinal products (ATMPs) and other new technologies largely produced by small and medium-sized enterprises.
